Search

Displaying results 3201 - 3210 of 5449 in total
  1. Drug

    Talmapimod

    go.drugbank.com/drugs/DB05412
    Investigational

    It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

  2. Drug

    Bromodiphenhydramine

    go.drugbank.com/drugs/DB01237
    Approved

    Bromodiphenhydramine is an ethanolamine antihistamine with antimicrobial property. Bromodiphenhydramine is used in the control of cutaneous allergies. Ethanolamine antihistamines produce marked sedation in most patients.

  3. Drug

    Ospemifene

    go.drugbank.com/drugs/DB04938
    Approved

    Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.

  4. Drug

    Alimemazine

    go.drugbank.com/drugs/DB01246
    ApprovedVet approvedWithdrawn

    A phenothiazine derivative that is used as an antipruritic.

  5. Drug

    Insulin human

    go.drugbank.com/drugs/DB00030
    ApprovedInvestigational

    Afrezza does not currently have Health Canada or European Medicines Agency approval for marketing in Canada or the EU. … While still available in the US, Afrezza has had similar concerns associated with its use, and had an FDA "black box" warning added to it to warn about use in patients with chronic lung disease.

    Mixtures: INSUMAN COMB 25 100I E/ML, INSUMAN COMB 25 100I E/ML
  6. Drug

    Roxatidine acetate

    go.drugbank.com/drugs/DB08806
    Investigational

    It is currently approved in South Africa under the tradename Roxit.

  7. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results

  8. Drug

    IDM-2

    go.drugbank.com/drugs/DB05293
    Experimental

    IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.

  9. Drug

    Aranidipine

    go.drugbank.com/drugs/DB09229
    Experimental

    [A31895] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[T88] … It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate.

  10. Drug

    Gliquidone

    go.drugbank.com/drugs/DB01251
    Approved

    It is an ATP-dependent K+ (KATP) channel blocker.

    Products: GLURENOR 30 MG TABLETTEN, Glurenorm 30 mg - Tabletten